|
Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). |
|
|
Employment - Berry Consultants |
Leadership - Berry Consultants |
Stock and Other Ownership Interests - Berry Consultants |
Consulting or Advisory Role - Berry Consultants |
Travel, Accommodations, Expenses - Berry Consultants |
|
|
Stock and Other Ownership Interests - Celmatix |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - CardioDx; CardioDx |
Patents, Royalties, Other Intellectual Property - Patents filed in conjunction with CardioDx work |
|
|
Other Relationship - Medidata Solutions |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
Travel, Accommodations, Expenses - Roche/Genentech |